Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Jul 25

PMID 35872912

Authors

Michela Chianca

Giorgia Panichella

Iacopo Fabiani

Alberto Giannoni

Serena LAbbate

Alberto Aimo

Annamaria Del Franco

Giuseppe Vergaro

Chrysanthos Grigoratos

Vincenzo Castiglione

Carlo Maria Cipolla

Antonella Fedele

Claudio Passino

Michele Emdin

Daniela Maria Cardinale

Affiliations

Soon will be listed here.

Abstract

Cancer and heart failure are the two leading causes of death in developed countries. These two apparently distinct clinical entities share similar risk factors, symptoms, and pathophysiological mechanisms (inflammation, metabolic disturbances, neuro-hormonal and immune system activation, and endothelial dysfunction). Beyond the well-known cardiotoxic effects of oncological therapies, cancer and heart failure are thought to be tied by a bidirectional relationship, where one disease favors the other and vice versa. In this context, biomarkers represent a simple, reproducible, sensitive and cost-effective method to explore such relationship. In this review, we recapitulate the evidence on cardiovascular and oncological biomarkers in the field of cardioncology, focusing on their role in treatment-naïve cancer patients. Cardioncological biomarkers are useful tools in risk stratification, early detection of cardiotoxicity, follow-up, and prognostic assessment. Intriguingly, these biomarkers might contribute to better understand the common pathophysiology of cancer and heart failure, thus allowing the implementation of preventive and treatment strategies in cardioncological patients.

Citing Articles

The Association between the JAK-STAT Pathway and Hypertension among Kenyan Women Diagnosed with Breast Cancer.

Gitau J, Kinyori G, Sayed S, Saleem M, Makokha F, Kirabo A bioRxiv. 2024; .

PMID: 38895458 PMC: 11185763. DOI: 10.1101/2024.06.07.597892.

Cardiology and oncology: a meeting of giants.

Dutra J, Macedo A, Peixoto T, Garcez J, Bacchiega B, De Marchi P Rev Assoc Med Bras (1992). 2024; 70(suppl 1):e2024S114.

PMID: 38865534 PMC: 11164274. DOI: 10.1590/1806-9282.2024S114.

Cardiovascular disease and cancer: shared risk factors and mechanisms.

Wilcox N, Amit U, Reibel J, Berlin E, Howell K, Ky B Nat Rev Cardiol. 2024; 21(9):617-631.

PMID: 38600368 PMC: 11324377. DOI: 10.1038/s41569-024-01017-x.

and are potential biomarkers associated with immune infiltration in heart failure and pan-cancer.

Wang J, Cai L, Huang G, Wang C, Zhang Z, Xu J Heliyon. 2024; 10(7):e28786.

PMID: 38576566 PMC: 10990859. DOI: 10.1016/j.heliyon.2024.e28786.

Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.

Attanasio U, Di Sarro E, Tricarico L, Di Lisi D, Armentaro G, Miceli S Biomolecules. 2024; 14(2).

PMID: 38397436 PMC: 10887095. DOI: 10.3390/biom14020199.

References

Schopfer D, Ku I, Regan M, Whooley M . Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J. 2014; 167(2):186-192.e1. DOI: 10.1016/j.ahj.2013.09.013. View

Chung H, Kim J, Kim H, Kwon M, Kim S, Shong M . GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep. 2017; 7(1):17238. PMC: 5722931. DOI: 10.1038/s41598-017-17574-w. View

Danese E, Montagnana M, Giudici S, Aloe R, Franchi M, Guidi G . Highly-sensitive troponin I is increased in patients with gynecological cancers. Clin Biochem. 2013; 46(12):1135-1138. DOI: 10.1016/j.clinbiochem.2013.04.029. View

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

Molfino A, Amabile M, Imbimbo G, Rizzo V, Pediconi F, Catalano C . Association between Growth Differentiation Factor-15 (GDF-15) Serum Levels, Anorexia and Low Muscle Mass among Cancer Patients. Cancers (Basel). 2021; 13(1). PMC: 7795323. DOI: 10.3390/cancers13010099. View

Watson C, Papula A, Poon G, Wong W, Young A, Druley T . The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020; 367(6485):1449-1454. DOI: 10.1126/science.aay9333. View

Emmerson P, Duffin K, Chintharlapalli S, Wu X . GDF15 and Growth Control. Front Physiol. 2018; 9:1712. PMC: 6277789. DOI: 10.3389/fphys.2018.01712. View

Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K . Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoS One. 2017; 12(6):e0178607. PMC: 5453551. DOI: 10.1371/journal.pone.0178607. View

Turk H, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R . Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol. 2003; 24(4):172-5. DOI: 10.1159/000074425. View

10.

Yan W, Wu F, Morser J, Wu Q . Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000; 97(15):8525-9. PMC: 26981. DOI: 10.1073/pnas.150149097. View

11.

Kwon Y, Lee H, Shim J, Lee Y . Serum carcinoembryonic antigen is positively associated with leukocyte count in Korean adults. J Clin Lab Anal. 2017; 32(3). PMC: 6817189. DOI: 10.1002/jcla.22291. View

12.

Hammarsten O, Mair J, Mockel M, Lindahl B, Jaffe A . Possible mechanisms behind cardiac troponin elevations. Biomarkers. 2018; 23(8):725-734. DOI: 10.1080/1354750X.2018.1490969. View

13.

Missov E, Calzolari C, Davy J, Leclercq F, Rossi M, Pau B . Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis. 1997; 8(8-9):537-41. View

14.

Pavo N, Arfsten H, Cho A, Goliasch G, Bartko P, Wurm R . The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. Sci Rep. 2019; 9(1):2554. PMC: 6385211. DOI: 10.1038/s41598-019-38867-2. View

15.

Park K, Gaze D, Collinson P, Marber M . Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017; 113(14):1708-1718. PMC: 5852618. DOI: 10.1093/cvr/cvx183. View

16.

Bracun V, Suthahar N, Shi C, de Wit S, Meijers W, Klip I . Established Tumour Biomarkers Predict Cardiovascular Events and Mortality in the General Population. Front Cardiovasc Med. 2021; 8:753885. PMC: 8692719. DOI: 10.3389/fcvm.2021.753885. View

17.

Wischhusen J, Melero I, Fridman W . Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11:951. PMC: 7248355. DOI: 10.3389/fimmu.2020.00951. View

18.

Berardi R, Caramanti M, Savini A, Chiorrini S, Pierantoni C, Onofri A . State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol. 2013; 88(1):75-86. DOI: 10.1016/j.critrevonc.2013.02.007. View

19.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

20.

Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View